Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Catheter Precision, Inc. on June 9, 2025, reporting events occurring on June 5, 2025. The Company is incorporated in Delaware and trades on the NYSE American under the symbol VTAK. The filing addresses a corporate action related to compensation for a recent financing transaction.
Key Financial Metrics
The filing does not provide specific financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the issuance of a warrant as partial compensation for services.
Material Changes and Events
- Warrant Issuance: On June 5, 2025, the Board of Directors approved the issuance of a placement agent common stock purchase warrant to Ladenburg Thalmann & Co., Inc.
- Warrant Terms: The warrant allows for the acquisition of 257,143 shares of common stock at an exercise price of $0.5424 per share.
- Purpose: This issuance serves as partial compensation for services provided in connection with a pipe financing that closed on May 12, 2025.
- Exercisability: The warrant is not immediately exercisable. It will become exercisable only upon approval by the Company's stockholders, which is expected at the annual meeting on July 25, 2025.
- Expiration: The warrant will terminate on June 6, 2030.
- Registration Status: Neither the warrant nor the underlying shares are registered under the Securities Act of 1933.
Outlook, Risks, and Management Commentary
Management indicates that stockholder approval for the warrant is anticipated at the 2025 Annual Meeting of Stockholders scheduled for July 25, 2025. The Company has filed a preliminary proxy statement (Schedule 14A) regarding this meeting. The filing includes a standard risk warning that this communication is not a substitute for the definitive proxy statement and urges investors to read all relevant SEC filings carefully.
Key Facts for Investor Verification
- Verify the outcome of the stockholder vote on the warrant at the July 25, 2025, annual meeting.
- Review the definitive proxy statement for details on the pipe financing closed on May 12, 2025.
- Monitor the dilution impact of 257,143 potential shares if the warrant is exercised at $0.5424 per share.
- Confirm the final terms of the warrant agreement filed as Exhibit 4.1.